ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Veraxa Biotech Holding AG
1.95
+0.0600
3.17%
盤後:
1.95
0.0000
0.00%
19:02 EDT
成交量:
8.01萬
成交額:
15.56萬
市值:
2.76億
市盈率:
9.10
高:
2.00
開:
1.86
低:
1.85
收:
1.89
52周最高:
27.36
52周最低:
1.70
股本:
1.41億
流通股本:
4,101.25萬
量比:
0.97
換手率:
0.20%
股息:
- -
股息率:
- -
每股收益(TTM):
0.2142
淨資產收益率:
-65.29%
總資產收益率:
-20.46%
市淨率:
7.11
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Veraxa Biotech Holding AG強化專利佈局,築牢核心技術平台與產品管線護城河
美股速递
·
07/29
Veraxa Biotech攜手OmniAb,推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展
美股速递
·
07/27
Veraxa Biotech股東大會全票通過所有議案,戰略靈活性獲強化,助力未來增長
美股速递
·
07/25
Veraxa Biotech任命Christoph Erkel為首席科學官,以推進Bitac®技術平台及產品組合
美股速递
·
07/23
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/VRXA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.95,"timestamp":1787342400000,"preClose":1.89,"halted":0,"volume":80147,"hourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03174603174603178,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"休市中","change":0.06,"latestTime":"08-21 16:00:00 EDT","open":1.86,"high":2,"low":1.8501,"amount":155628,"amplitude":0.079312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.87,"preClose":1.89,"latestTime":"09:27 EDT","volume":304,"amount":569.2840192,"timestamp":1787318870054,"change":-0.02,"changeRate":-0.010582,"amplitude":0.015873},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.967295187072036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-20.46%","roe":"-65.29%","lyrEps":0,"volumeRatio":0.967295187072036,"shares":141407813,"dividePrice":0,"high":2,"amplitude":0.079312,"preClose":1.89,"low":1.8501,"week52Low":1.7,"pbRate":"7.11","week52High":27.36,"institutionHeld":0,"latestPrice":1.95,"eps":0.2142,"divideRate":0,"volume":80147,"delay":0,"ttmEps":0.2142,"open":1.86,"prevYearClose":18.65,"prevWeekClose":1.87,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.87,"twentyDayClose":1.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-21","current":9.103641,"percent":0,"low":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"high":-1.331869,"avg":-1.34261,"sd":0.010741,"marketCap":47660725},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725}],"updateTime":1787513706063},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1178040350","title":"Veraxa Biotech Holding AG強化專利佈局,築牢核心技術平台與產品管線護城河","url":"https://stock-news.laohu8.com/highlight/detail?id=1178040350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178040350?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322874,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正全力扩充其专利组合,旨在为公司的核心技术平台与候选产品构建起坚实的知识产权堡垒。这一举措,不仅彰显了企业对创新成果的深度保护,更预示着其在生物科技领域长期战略布局的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183111407","title":"Veraxa Biotech攜手OmniAb,推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1183111407","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183111407?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:01","pubTimestamp":1785150073,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正积极推进其新型双特异性抗体药物偶联物(ADC)项目Vxa-222。这一里程碑式的进展,源自其与OmniAb共同开展的发现合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130159461","title":"Veraxa Biotech股東大會全票通過所有議案,戰略靈活性獲強化,助力未來增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1130159461","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130159461?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 04:06","pubTimestamp":1784923570,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG在临时股东大会上传来捷报——所有提案均获股东一致通过。此举旨在增强公司的战略灵活性,为未来扩张奠定坚实基础。会议审议的各项决议,从资本结构调整到管理层授权,无不彰显出公司对长远布局的深远考量。通过赋予董事会更大的操作空间,Veraxa Biotech将能够更敏捷地应对市场波动,灵活调配资源。随着本次股东大会的圆满落幕,Veraxa Biotech正以更优化的治理结构和更清晰的路径,迎接下一阶段的成长挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169769269","title":"Veraxa Biotech任命Christoph Erkel為首席科學官,以推進Bitac®技術平台及產品組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1169769269","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169769269?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 19:08","pubTimestamp":1784804909,"startTime":"0","endTime":"0","summary":"生物技术公司Veraxa Biotech Holding AG (VRXA) 宣布,任命Christoph Erkel博士为其首席科学官。这一关键人事任命旨在加速其Bitac®技术平台的开发进程,并推动整体产品组合的拓展与深化。Erkel博士在药物研发与技术创新领域拥有丰富的经验,他的加入预计将为公司核心技术的发展注入新的动力,并助力其管线产品向临床应用阶段迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VRXA\",params:#limit:6,delay:false,,,undefined,":[]}}